403 related articles for article (PubMed ID: 27037230)
1. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
van Sonderen A; Schreurs MW; de Bruijn MA; Boukhrissi S; Nagtzaam MM; Hulsenboom ES; Enting RH; Thijs RD; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Neurology; 2016 May; 86(18):1692-9. PubMed ID: 27037230
[TBL] [Abstract][Full Text] [Related]
2. Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
Yeo T; Chen Z; Yong KP; Wong PYW; Chai JYH; Tan K
J Neurol Sci; 2018 Aug; 391():64-71. PubMed ID: 30103974
[TBL] [Abstract][Full Text] [Related]
3. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis.
van Sonderen A; Petit-Pedrol M; Dalmau J; Titulaer MJ
Nat Rev Neurol; 2017 May; 13(5):290-301. PubMed ID: 28418022
[TBL] [Abstract][Full Text] [Related]
4. From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time.
van Sonderen A; Schreurs MW; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Autoimmun Rev; 2016 Oct; 15(10):970-4. PubMed ID: 27485013
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
Bastiaansen AEM; van Sonderen A; Titulaer MJ
Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
[TBL] [Abstract][Full Text] [Related]
6. Detection of LGI1 and CASPR2 antibodies with a commercial cell-based assay in patients with very high VGKC-complex antibody levels.
Yeo T; Chen Z; Chai JYH; Tan K
J Neurol Sci; 2017 Jul; 378():85-90. PubMed ID: 28566186
[TBL] [Abstract][Full Text] [Related]
7. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.
Klein CJ; Lennon VA; Aston PA; McKeon A; O'Toole O; Quek A; Pittock SJ
JAMA Neurol; 2013 Feb; 70(2):229-34. PubMed ID: 23407760
[TBL] [Abstract][Full Text] [Related]
8. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.
Lang B; Makuch M; Moloney T; Dettmann I; Mindorf S; Probst C; Stoecker W; Buckley C; Newton CR; Leite MI; Maddison P; Komorowski L; Adcock J; Vincent A; Waters P; Irani SR
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):353-361. PubMed ID: 28115470
[TBL] [Abstract][Full Text] [Related]
9. Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
Bien CG; Bien CI; Dogan Onugoren M; De Simoni D; Eigler V; Haensch CA; Holtkamp M; Ismail FS; Kurthen M; Melzer N; Mayer K; von Podewils F; Rauschka H; Rossetti AO; Schäbitz WR; Simova O; Witt K; Höftberger R; May TW
J Neurol; 2020 Jul; 267(7):2101-2114. PubMed ID: 32246252
[TBL] [Abstract][Full Text] [Related]
10. Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia.
Kannoth S; Nambiar V; Gopinath S; Anandakuttan A; Mathai A; Rajan PK
Neurol Sci; 2018 Mar; 39(3):455-460. PubMed ID: 29264691
[TBL] [Abstract][Full Text] [Related]
11. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.
Michael S; Waters P; Irani SR
Pract Neurol; 2020 Oct; 20(5):377-384. PubMed ID: 32595134
[TBL] [Abstract][Full Text] [Related]
12. Morvan syndrome: clinical and serological observations in 29 cases.
Irani SR; Pettingill P; Kleopa KA; Schiza N; Waters P; Mazia C; Zuliani L; Watanabe O; Lang B; Buckley C; Vincent A
Ann Neurol; 2012 Aug; 72(2):241-55. PubMed ID: 22473710
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
[TBL] [Abstract][Full Text] [Related]
14. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex.
Montojo MT; Petit-Pedrol M; Graus F; Dalmau J
Neurologia; 2015 Jun; 30(5):295-301. PubMed ID: 24485651
[TBL] [Abstract][Full Text] [Related]
15. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.
Binks SNM; Klein CJ; Waters P; Pittock SJ; Irani SR
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):526-534. PubMed ID: 29055902
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of voltage-gated potassium channel–complex antibodies in children.
Hacohen Y; Singh R; Rossi M; Lang B; Hemingway C; Lim M; Vincent A
Neurology; 2015 Sep; 85(11):967-75. PubMed ID: 26296514
[TBL] [Abstract][Full Text] [Related]
17. Emerging psychiatric syndromes associated with antivoltage-gated potassium channel complex antibodies.
Prüss H; Lennox BR
J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1242-1247. PubMed ID: 27435086
[TBL] [Abstract][Full Text] [Related]
18. Cramp-fasciculation syndrome in patients with and without neural autoantibodies.
Liewluck T; Klein CJ; Jones LK
Muscle Nerve; 2014 Mar; 49(3):351-6. PubMed ID: 23836298
[TBL] [Abstract][Full Text] [Related]
19. Neuronal antibodies in pediatric epilepsy: Clinical features and long-term outcomes of a historical cohort not treated with immunotherapy.
Wright S; Geerts AT; Jol-van der Zijde CM; Jacobson L; Lang B; Waters P; van Tol MJ; Stroink H; Neuteboom RF; Brouwer OF; Vincent A
Epilepsia; 2016 May; 57(5):823-31. PubMed ID: 26996997
[TBL] [Abstract][Full Text] [Related]
20. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.
Gadoth A; Pittock SJ; Dubey D; McKeon A; Britton JW; Schmeling JE; Smith A; Kotsenas AL; Watson RE; Lachance DH; Flanagan EP; Lennon VA; Klein CJ
Ann Neurol; 2017 Jul; 82(1):79-92. PubMed ID: 28628235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
